| ACMG | American College of Medical Genetics and Genomics |
| AMP | Association for Molecular Pathology |
| ASCO | American Society of Clinical Oncology |
| BC | Breast cancer |
| CI | Confidence interval |
| CPSR | Cancer Predisposition Sequencing Reporter |
| DNA | Deoxyribonucleic acid |
| DSS | Dataiku Data Science Studio |
| ER | Estrogen receptor |
| FDA | U.S. Food and Drug Administration |
| GenAI | Generative artificial intelligence |
| GPV | Germline pathogenic variant |
| HER2 | Human epidermal growth factor receptor 2 |
| HRD | Homologous recombination deficiency |
| HRR | Homologous recombination repair |
| IQR | Interquartile range |
| LOH | Loss of heterozygosity |
| LP | Likely pathogenic |
| NGS | Next-generation sequencing |
| P | Pathogenic |
| PARP | Poly(ADP-ribose) polymerase |
| PARPi | Poly(ADP-ribose) polymerase inhibitor |
| PR | Progesterone receptor |
| SD | Standard deviation |
| SF | Secondary findings |
| TNBC | Triple-negative breast cancer |
| VUS | Variant of uncertain significance |
| WES | Whole-exome sequencing |